• 대한방사선치료학회지
• /
• 제33권
• /
• pp.109-116
• /
• 2021

목 적: 본 연구는 표면유도환자셋업(Surface-Guided Patient Setup, SGPS)을 활용한 Markerless환자(피부에 표시를 시행하지 않은 환자)와 레이저기반환자셋업(Laser-Based Patient Setup, LBPS)을 활용한 Marker환자(피부에 표시를 시행한 환자)를 영상유도방사선치료(Image Guided Radiotherapy, IGRT)로 시행했을 때 환자 위치 정확도를 비교하여 SGPS의 유용성을 평가하는데 목적이 있다. 대상 및 방법: 3개의 카메라를 이용한 광학 표면 스캐닝시스템을 사용하여 SGPS로 초기 셋업한 Markerless 환자와 환자 피부에 그려진 Marker와 레이저를 정렬하는 LBPS로 초기 셋업한 Marker환자의 IGRT시 위치 오차를 비교하였다. SGPS,LBPS 모두 각각 전립선암 환자 20명, 뇌정위적방사선수술(Stereotactic Radiation Surgery, SRS) 환자 10명을 대상으로 시행하였고 SGPS의 경우는 추가로 유방암 환자 60명을 대상으로 시행하였다. 모두 CBCT 또는 OBI를 사용하여 IGRT를 시행하였다. 자동위치교정시스템(Auto-Matching System)을 이용하여 6방향(6 Degree Of Freedom, 6 DoF)의 위치 오차를 획득하였고 치료계획시스템에서 Offline-Review를 이용하여 비교, 분석하였다. 결 과 : 전립선암환자의 SGPS와 LBPS의 RMS(Root Mean Square) 차이는 Vrt -0.02cm, Log -0.02cm, Lat -0.01cm, Pit -0.01°, Rol -0.01°, Rtn -0.01°이였고 SRS 환자는 Vrt 0.02cm, Log -0.05cm, Lat 0.00cm, Pit -0.30°, Rol -0.15°, Rtn -0.33°으로 두 부위 모두 큰 차이가 없었다. 유방암환자의 IGRT기준 RMS는 Vrt 0.26, Log 0.21, Lat 0.15, Pit 0.81, Rol 0.49, Rtn 0.59으로 나타났다. 결 론 : 본 연구의 결과 LBPS 대비 SGPS의 위치 오차 값은 전립선암 환자와 SRS 환자의 경우 큰 차이를 보이지 않았다. 추가로 실시한 SGPS의 유방암 환자의 경우에도 IGRT기준으로 위치 오차 값이 크지 않았다. 따라서 환자 피부 표시를 필요로 하지 않는 큰 장점을 가진 SGPS로 LBPS를 대체하기에 유용할 것으로 사료된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권19호
• /
• pp.8441-8445
• /
• 2014

Background: Paired-like homeodomain transcription factor 2 (PITX2) is another new marker in breast carcinoma since hypermethylation at P2 promoter of this gene was noted to be associated with poor prognosis. We investigated the expression of PITX2 protein using immunohistochemistry in invasive ductal carcinoma and its association with the established growth receptors such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2). Methods: We conducted a cross sectional study using 100 samples of archived formalin-fixed paraffin embedded tissue blocks of invasive ductal carcinoma and stained them with immunohistochemistry for PITX2, ER, PR and HER2. All HER2 with scoring of 2+ were confirmed with chromogenic in-situ hybridization (CISH). Results: PITX2 protein was expressed in 53% of invasive ductal carcinoma and lack of PITX2 expression in 47%. Univariate analysis revealed a significant association between PITX2 expression with PR (p=0.001), ER (p=0.006), gland formation (p=0.044) and marginal association with molecular subtypes of breast carcinoma (p=0.051). Combined ER and PR expression with PITX2 was also significantly associated (p=0.003) especially in double positive cases. Multivariate analysis showed the most significant association between PITX2 and PR (RR 4.105, 95% CI 1.765-9.547, p=0.001). Conclusion: PITX2 is another potential prognostic marker in breast carcinoma adding significant information to established prognostic factors of ER and PR. The expression of PITX2 together with PR may carry a very good prognosis.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권7호
• /
• pp.3037-3046
• /
• 2012

The diffuse large B-cell lymphoma (DLBCL) encompasses two major groups of tumors with uneven survival outcomes - germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB). In the present study, we investigated the expression of GCB markers (BCL-6 and CD10) and non-GCB markers (CD138 and MUM-1) in an effort to evaluate their prognostic value. Paraffin-embedded tumor biopsies of 46 Jordanian DLBCL patients were analyzed, retrospectively, by immunohistochemistry to investigate the expression of BCL-6, CD10, CD138 and MUM-1. In addition, survival curves were calculated with reference to marker expression, age, sex and nodal involvement. Positive expression of BCL-6, CD10, CD138 and MUM-1 was shown in 78%, 61%, 39% and 91% of the cases, respectively, that of BCL-6 being associated with better overall survival (p = 0.02), whereas positive CD138 was linked with poor overall survival (p = 0.01). The expression of CD10 and MUM-1 had no impact on the overall survival. Among the clinical characteristics studied, diagnosis at an early age, nodal involvement and maleness were associated with a higher overall survival for DLBCL patients. Our results underline the importance of BCL-6 as a marker of better prognosis and CD138 as a marker of poor prognosis for DLBCL patients.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6187-6191
• /
• 2015

In 1997 for the first time, survivin was described by Amborsini et al. as an anti-apoptotic protein. Subsequent studies revealed that survivin is a multifunctional protein that plays critical roles in several crucial cell processes such as apoptosis, cell cycle, chromosome movement, mitosis and cellular stress responses. Moreover, it's overexpression in cancer cells versus normal cells is associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival. All of these features make survivin a promising target for cancer therapy. Here, we review the potential characteristics of survivin as a tumor marker.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7491-7496
• /
• 2015

Background: Biomarkers in breast neoplasms provide invaluable information regarding prognosis and help determining the optimal treatment. We investigated the possible correlation between cancer stem cell (CSC) markers (CD133, and ALDH1) in invasive ductal breast carcinomas with some clinicopathological parameters. Aim: To assess the correlation between expression of cancer stem cell (CSC) markers (CD133, and ALDH1) and clinicopathological parameters of invasive ductal breast carcinomas. Materials and Methods: Immunohistochemical analysis of CD133 and ALDH1 was performed on a series of 120 modified radical mastectomy (MRM) specimens diagnosed as invasive ductal breast carcinoma. Results: Expression of both CD133 and ALDH1 was significantly changed and related to tumor size, tumor stage (TNM), and lymph node metastasis. A negative correlation between CD133 and ALDH1 was found. Conclusions: Detecting the expression of CD133 and ALDH1 in invasive ductal breast carcinomas may be of help in more accurately predicting the aggressive properties and determining the optimal treatment.

• Genomics & Informatics
• /
• 제13권3호
• /
• pp.86-89
• /
• 2015

Because there are clear molecular differences entailing different treatment effectiveness between Korean and non-Korean cancer patients, identifying distinct molecular characteristics of Korean cancers is profoundly important. Here, we report a web-based data repository, namely Korean Cancer Genome Database (KCGD), for searching gene signatures associated with Korean cancer patients. Currently, a total of 1,403 cancer genomics data were collected, processed and stored in our repository, an ever-growing database. We incorporated most widely used statistical survival analysis methods including the Cox proportional hazard model, log-rank test and Kaplan-Meier plot to provide instant significance estimation for searched molecules. As an initial repository with the aim of Korean-specific marker detection, KCGD would be a promising web application for users without bioinformatics expertise to identify significant factors associated with cancer in Korean.

• BMB Reports
• /
• 제50권5호
• /
• pp.233-234
• /
• 2017

Aberrant expression of the polypeptide N-acetyl-galactosaminyltransferase (GALNTs) has been associated with cancer, but their function(s) in metastasis remains elusive. We have recently identified GALNT14, one of the O-GalNAc glycosylation-initiating enzymes, as a prognostic marker for pulmonary relapse in breast cancer patients. Furthermore, we showed that GALNT14 promotes lung metastasis by the following novel mechanisms: 1) enhancing metastasis initiation by inhibiting the anti-metastatic effect of BMP produced from the lung stroma, 2) exploiting growth signals (e.g. FGF) supplied by macrophages, for their growth into macrometastases in the lung environment. These multi-faceted roles of GALNT14 in lung metastasis are achieved by GALNT14-mediated inhibition and activation of the BMP and FGF signaling pathways, respectively. The link among GALNT14, its downstream pathways and lung metastasis, provides us with an opportunity to develop effective therapeutic intervention for breast cancer.

• Nuclear Medicine and Molecular Imaging
• /
• 제40권2호
• /
• pp.132-140
• /
• 2006

Well-differentiated thyroid cancer is the most common endocrine malignancy with an increasing incidence. Most patients with well-differentiated thyroid caner have a favorable prognosis with high survival rate. While surgery and radioiodine therapy is sufficient treatment for the majority of patients with differentiated thyroid cancer, a minority of these patients experiences progressive, life-threatening growth and metastatic spread of the disease. Because there is no prospective controlled study to evaluate the differences of management of thyroid cancer, it is hard to choose the best treatment option. And there are still lots of controversies about the management of this disease, such as surgical extent, proper use of radioiodine for remnant ablation and therapy, use of rhTSH instead of withdrawal of thyroid hormone, long-term follow-up strategy, thyroglobulin as a tumor marker, etc. In this review, recent data related to these conflicting issues and recent advances in diagnosis, radioiodine therapy and long-term monitoring of well-differentiated thyroid cancer are summarized.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권19호
• /
• pp.8429-8433
• /
• 2014

Circulating tumor cells (CTCs) are believed to be particularly important and a reliable marker of malignancy. However, the prognostic significance of CTCs detected in patients with small cell lung cancer (SCLC) is still unclear. We therefore aimed to assess the prognostic relevance of CTCs using a meta-analysis. We searched PubMed for relevant studies and statistical analyses were conducted to calculate the hazard ratio (HR) and 95% confidence intervals (CIs) using fixed or random-effect models according to the heterogeneity of included studies. A total of 7 papers covering 440 SCLC patients were combined in the final analysis. The meta-analysis revealed that CTCs were significantly associated with shorter overall survival (HR=1.9; 95%CI: 1.19-3.04; Z=2.67; P<0.0001) and progression-free survival (HR=2.6; 95%CI: 1.9-3.54; Z=6.04; P<0.0001). The results thus suggest that the presence of CTCs indicates a poor prognosis in patients with SCLC. Further well-designed prospective studies are required to explore the clinical applications of CTCs in SCLC.

• BMB Reports
• /
• 제44권9호
• /
• pp.595-600
• /
• 2011

Pax 6, a member of the paired box (Pax) family, has been implicated in oncogenesis. However, its therapeutic potential has been never examined in breast cancer. To explore the role of Pax6 in breast cancer development, a lentivirus based short hairpin RNA (shRNA) delivery system was used to knockdown Pax6 expression in estrogen receptor (ER)-positive (MCF-7) and ER-negative (MDA-MB-231) breast cancer cells. Effect of Pax6 silencing on breast cancer cell proliferation and tumorigenesis was analyzed. Pax6-RNAi-lentivirus infection remarkably downregulated the expression levels of Pax6 mRNA and protein in MCF-7 and MDA-MB-231 cells. Accordingly, the cell viability, DNA synthesis, and colony formation were strongly suppressed, and the tumorigenesis in xenograft nude mice was significantly inhibited. Moreover, tumor cells were arrested at G0/G1 phase after Pax6 was knocked down. Pax6 facilitates important regulatory roles in breast cancer cell proliferation and tumor progression, and could serve as a diagnostic marker for clinical investigation.